Pathology Disease Articles & Analysis
24 news found
Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. ...
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, the naked eye’s powers are limited. That’s where OCT technology comes in handy. OCTs have become a standard of care that every practice ...
Creative Biogene unveiled a rich portfolio of efficient cell apoptosis assay kits targeted to detect mitochondrial permeability transition pore (MPTP) as well as mitochondrial membrane potential (MMP) to assist researchers in mitochondrial studies. Mitochondrial dysfunction has been linked to a variety of market therapeutics and pathological diseases. Therefore, studying or maintaining ...
Digital pathology and cancer informatics provider Inspirata is proud to announce a new partnership with precision pathology company SpIntellx, further strengthening and diversifying Inspirata’s growing partner ecosystem. This partnership allows Inspirata and SpIntellx customers the seamless integration of Dynamyx and HistoMapr-Breast, resulting in a more efficient breast core-biopsy ...
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that A. Stewart Campbell, Ph.D., chief executive officer, will participate in a panel titled “Placing Patients At The Center” at the Longwood Healthcare Leaders Spring MIT webconference ...
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions, today announced that its scientific founder and California Institute of Technology (Caltech) Professor, Sarkis Mazmanian, Ph.D., will be presenting at TACA’s Autism Action Conference, taking place virtually from April 8-9, 2022. The ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) ...
Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological ...
Open-label study showed Axial’s Lead Candidate, AB-2004, is safe and well-tolerated in an adolescent ASD cohort AB-2004 lowered blood and urinary levels of gut-derived metabolites and significantly improved irritability and anxiety Research supports company’s clinical development strategy focused on gut-targeted therapeutics for managing irritability associated with autism ...
Proceeds will support Axial's randomized, controlled Phase 2b clinical trial for lead candidate, AB-2004, a molecular therapeutic to treat irritability in children with autism Funding positions company for platform and pipeline growth Completion of new round brings total investment in company to $91.5 million to date Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
Exosomes, small lipid bilayer-enclosed particles of endosomal origin, are a subset of extracellular vesicles (EVs) that are secreted by most cell types. They are spherical, bilayered proteolipids and show a diverse mixture of exosomal nucleic acids (mRNA and non-coding RNA), proteins, and lipids, among which exosomal proteins play a key role in the pathological process of various diseases. At ...
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. Stewart Campbell, Ph.D. as Chief Executive Officer (CEO). Dr. Campbell will also serve as a ...
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake commercial scale manufacturing to support U.S. market launch AB2 Bio Ltd., a Swiss advanced clinical-stage biotech company developing innovative therapies for the treatment of severe systemic ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced that the company was awarded a $3.19 million grant from the National Institute on Aging (NIA) at National Institutes of Health (NIH). The three-year SBIR/STTR Commercialization Readiness Pilot ...
Optos plc, the leading medical retinal imaging company, part of Nikon Corporation, is pleased to announce the launch of Silverstone at the American Academy of Ophthalmology, San Francisco, CA. Silverstone is the first of its kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture optomap® ...
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017. The award will further support ...
ByDiamiR